Head-up Position and High Quality Cardiopulmonary Resuscitation in OHCA (GRAVITY)

May 16, 2023 updated by: University Hospital, Grenoble

Head-up Position, Active Compression-decompression Mechanical Cardiopulmonary Resuscitation and Impedance Threshold Device to Improve Outcomes in Out-of-hospital Cardiac Arrest. A Multicenter Prospective Controlled Quasi-experimental Trial

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Elevation of the head and thorax, also known as Head-up cardiopulmonary resuscitation (HUP CPR), has been studied extensively in pigs in ventricular fibrillation (VF). HUP combined with active compression decompression and impedance threshold device (ACD+ITD) CPR improves vital organ perfusion and results in a doubling of cerebral perfusion when compared with the same method of CPR in the flat or horizontal plane. HUP CPR enhances the drainage of venous blood from the brain, lowers central venous pressures, reduces intracranial pressures during the decompression phase of CPR, redistributes blood flow through the lungs during CPR, and may reduce brain edema. These mechanisms collectively contribute to improved blood flow and less injury to the brain during CPR. These benefits are due in large part to the effects of gravity on the physiology of HUP CPR. Importantly, HUP CPR is dependent upon a means of generating enough forward flow to adequately pump blood "uphill" to the brain.

Animal studies have shown that HUP CPR must be performed in a specific manner to be effective. For example, conventional standard CPR is insufficient, by itself, for effective HUP CPR. Additional means to enhance circulation are needed, such as concurrent use of the ITD and ACD CPR devices. ACD+ITD CPR alone has been shown to improve hemodynamics and survival with favorable neurologic outcome in several human randomized control trials. Animal studies have shown that HUP CPR is best with the combination of ACD+ITD CPR. Studies have shown that CPR must be initiated before elevating the head. Studies have also shown that HUP CPR is dependent upon the time it takes to elevate the head to the HUP. Elevation of the head and thorax should optimally take place over a 2-minute period of time from a flat position to the maximum head up elevation level in order to optimize cerebral perfusion pressures. Too rapid an elevation of the head and thorax can result in a reduction in cerebral arterial pressure when compared with flat CPR.

In this proposed pilot study, CPR will be performed manually before the patient is placed on a controlled mechanical elevation device (Elegard, Minnesota Resuscitation Solutions LLC, USA). An ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated. Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

The proposed feasibility clinical study will be the first ever to test the fully integrated system of ACD+ITD HUP CPR.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
126

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
    • Isère
      • Grenoble, Isère, France, 38000
        • SAMU 38
    • Meurthe-et-Moselle
      • Nancy, Meurthe-et-Moselle, France, 54000
        • SAMU 54 - CHU Nancy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age > 18 years old on enrollment
  • Witnessed out-of-hospital cardiac arrest

Exclusion Criteria:

  • Obvious pregnancy at inclusion
  • Cardiac arrest of traumatic origin (including drowning or hanging)
  • Cardiac arrest for which resuscitation seems unjustified (inevitable death, terminally ill irreversible condition, too long duration of cardiac arrest, advance personal directives of no-resuscitation)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control Group

During the pre-intervention period, patients will receive standard CPR in the two study groups. Standard CPR will be performed according to the current guidelines.

The only changes in current practice for the control will be the monitoring of EtCO2 and cerebral oxymetry as early as possible for the firefighter. ETCO2 will be recorded using a small portable ETCO2 monitor (EMMA, Masimo, USA). EMS first responders will receive a specific training in both group to use, recording, and reporting of ETCO2 value during CPR. This device has CE mark (see related CE mark and user manual). Cerebral oximetry will be recorded using a new small portable device (HR500, Nonin, USA). This device allows using an easy to use adhesive sensor with remote Bluetooth connection to a smartphone sized monitor.
Active Comparator: Assigned Intervention
During the post-intervention period, patients assigned in the intervention group will receive the evaluated intervention (i.e., HUP and ACD-ITD CPR HUP using the 3 devices in combinations, Elegard, Lucas AD and ITD-16)
Device: Head UP Position

CPR will be performed manually before the patient is placed on a controlled mechanical elevation device who raises the head and thorax, also known as the head-up position (HUP-Elegard, Minnesota Resuscitation Solutions LLC, USA).

Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. After performing (LUCAS AD + ITD CPR, see other interventions below) for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput.

Device: Impedance Threshold Device
An an impedance threshold device ITD-16 (ResQPOD-16, Zoll, USA) will be placed on the patient's airway before the head is elevated.
Device: New Automated CPR
Automated CPR will be initiated as soon as feasible using a new automated CPR mechanical compression device that provides full active compression-decompression CPR (LUCAS-AD, Stryker, USA).

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Maximum End-tidal carbon dioxide (ETCO2)
Time Frame: Day 0
The maximum value of ETCO2 during CPR before ROSC measured after a washout period of 4 positive pressure ventilations (~30 seconds with 30:2 compression: ventilation ratio) will be recorded. ETCO2 value reflects both cardiac output (CO) and pulmonary blood flow, and is an indirect indicator of coronary perfusion pressure during CPR. Levels of ETCO2 > 10-15 mmHg have been correlated with return of spontaneous circulation (ROSC) and survival in both animal and human models of cardiac arrest.
Day 0

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Return of spontaneous circulation (ROSC)
Time Frame: Day 0
Proportion of patients who's recovered a spontaneous circulation after CPR
Day 0
Alive at hospital admission
Time Frame: Day 0
Vital status at hospital admission
Day 0
Survival to hospital discharge
Time Frame: up to 30 days
Vital status at hospital discharge
up to 30 days
Survival at 30 days
Time Frame: 30 days
Vital status at 30 days
30 days
First recorded rhythm
Time Frame: Day 0
First recorded rhythm and rhythm recorded by EMS (asystole, ryhtme without pulse, ventricular fibrillation or ventricular tacycardia and spontaneous circulation)
Day 0
Changes in heart rhythm from ventricular fibrillation (VF)
Time Frame: Day 0
Proportion of patients who's with changes in heart rhythm from VF to non-VF rhythm and vice versa during the EMS intervention
Day 0
Signs of life
Time Frame: Day 0
Presence of agonal respirations and other signs of life (pupillary response, movement during CPR) recorded by ALS
Day 0
Re-arrest rates
Time Frame: Day 0
We calculated the proportion of patients who's recovered another cardiac arrest during CPR (supported by ALS and EMS)
Day 0
Non-invasive arterial O2
Time Frame: Day 0
Non-invasive arterial O2 saturation values during CPR recorded by EMS
Day 0
End-tidal carbon dioxide (ETCO2) after CPR initiation
Time Frame: Day 0
We compared the difference in ETCO2 values between baseline (i.e., within 2 minutes of CPR initiation) and repeated (i.e., within 4 minutes of CPR initiation) measures during the CPR (recorded by ALS and EMS intervention)
Day 0
Non-invasive cerebral oximetry (rsO2)
Time Frame: Day 0
Non-invasive cerebral oximetry (rsO2) values during CPR repeated (i.e., within 4 minutes of CPR initiation) measures recorded by ALS and EMS intervention
Day 0
Left Ventricular (LV) function
Time Frame: Day 0
LV function will be measured by echocardiography within 12 hours of ROSC at hospital
Day 0
Non-invasive measurement of blood pressure
Time Frame: Day 0
Non-invasive measurement of blood (systolic, diastolic and mean blood pressure) pressure during CPR
Day 0
Intubation difficulty
Time Frame: Day 0
Intubation difficulty assessed by the Intubation Difficulty Scale score. Score equal at 0 will be considered to easy intubation, score between 0 and 5 will be considered to slight difficulty, score more than 5 will be considered to moderate to major difficulty and score equal to infinite will be considered to impossible intubation
Day 0
Neuron specific enolase
Time Frame: Day 0 and 24hours
Serum Neuron specific enolase was measured at admission and 24h after hospital admission
Day 0 and 24hours
S100 protein
Time Frame: Day 0 and 24hours
Serum S100 protein was measured- at admission and 24h after hospital admission
Day 0 and 24hours
Arterial Blood gases
Time Frame: Day 0
Arterial blood gases (PaO2 partial pressure of oxygen, PCO2 partial pressure of cardon dioxide, pH, HCO3- bicarbonates and SaO2 oxygen saturation) were measured at hospital admission
Day 0
Serum lactate concentration
Time Frame: Day 0
The serum lactate concentration was measured at hospital admission
Day 0
Serum d-dimer concentration
Time Frame: Day 0 and 24hours
Serum d-dimer concentration was measured at 4hour and 24 hour after admission
Day 0 and 24hours
Troponin C serum concentration
Time Frame: Day 0 and 24hours
Troponin C serum concentration was measured at 4hour and 24 hour after admission
Day 0 and 24hours
Creatinine concentration
Time Frame: Day 0 and 24hours
Serum creatinine concentration was measured at 4hour and 24 hour after admission
Day 0 and 24hours
Transaminases concentration
Time Frame: Day 0 and 24hours
Serum transaminases concentration (ASAT: aspartate aminotransferases and ALAT: alanine aminotransferases) were measured at 4hour and 24 hour after admission
Day 0 and 24hours
Imaging
Time Frame: 12 hours
Head CT will be performed within 12 hours of ROSC. Analysis will include the white to gray matter ratio
12 hours
End-tidal carbon dioxide between witnessed and unwitnessed cardiac arrest out-of-hospital cardiac arrest
Time Frame: Day 0
We compared the difference in maximum ETCO2 during CPR between values recorded for witnessed and unwitnessed cardiac arrest
Day 0
ROSC for witnessed and unwitnessed cardiac arrest
Time Frame: Day 0
Proportion of patients who's recovered a spontaneous circulation after CPR between witnessed and unwitnessed cardiac arrest
Day 0
Survival to hospital admission for witnessed and unwitnessed cardiac arrest
Time Frame: Day 0
Vital status at hospital admission between witnessed and unwitnessed cardiac arrest
Day 0
Survival to hospital discharge for witnessed and unwitnessed cardiac arrest
Time Frame: Up to 30 days
Vital status at hospital discharge between witnessed and unwitnessed cardiac arrest
Up to 30 days
Neurological functional status between witnessed and unwitnessed cardiac arrest
Time Frame: Up to 30 days
As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disbility ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We consired to a score less or equal to 3 will be considered as favourable neurologic outcome
Up to 30 days
Neurological functional status
Time Frame: Day 30
As measured by using the modified Rankin Scale (mRS). A score equal to 0 = no symptoms at all, A score equal to 1 = no significant disability, despite symptoms ; able to carry out all usual duties and activities A score equal to 2 = slight disability ; unable to carry out all previous activities but able to look after own affairs A score equal to 3 = moderate disability ; requiring some help, but able to walk without assistance A score equal to 4 = moderately severe disability ; unable to walk without assistance and unable to attend to own bodily needs without assistance A score equal to 5 = severe disability ; bedridden, incontinent and requiring constant nursing care and attention We considered to a score less or equal to 3 will be considered as favourable neurologic outcome
Day 30

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Grenoble

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Monique Sorentino, Chu Grenoble Alpes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 9, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 17, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 20, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 17, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 20, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 25, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 18, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 16, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • GRAVITY

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Study protocol will be submitted for publication. IPD will be shared with other researcher

IPD Sharing Time Frame

Data will be available within 6 months of study completion

IPD Sharing Access Criteria

Data will be available with no restriction

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiac Arrest

Clinical Trials on Head UP Position

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings